Six People With Rheumatoid Arthritis Were Given a Cancer Therapy and Three Have Been Off All Medication Since

Professor Gerhard Kroenke, who led the work at the Charite in Berlin, framed the outcome as particularly remarkable given that none of the established treatments had previously relieved these patients adequately. Which is a careful way of saying the same thing.

The safety numbers

All six had cytokine release syndrome, at mild to moderate grades. There were no severe neurological complications, no serious adverse events, and infections were rare.

Cytokine release syndrome in every participant sounds alarming and is expected. It is the immune system reacting to a large number of cells being killed quickly, it is the signature side effect of CAR T therapy in cancer, and mild to moderate is the range you hope for. What would have stopped this programme is severe neurotoxicity, and it did not appear.

The unresolved risk is not in the trial. It is in what an engineered cell therapy costs, what a manufacturing failure means for a single patient, and what the ten year picture looks like for a young person given a therapy whose oldest recipients are cancer patients treated a decade ago. None of that is answerable yet.

What happens next

A second phase of ten more patients, comparing this against an already approved drug that also targets B cells.

That is exactly the right next question, and it is a more demanding one than it sounds. The comparison is not against placebo, it is against the existing B cell therapy, which means the trial has to show that the expensive engineered version does something the cheap antibody does not. If it does, autoimmune medicine changes. If the two look similar at a year, this becomes a very interesting result with no route to a clinic.

How to read results like this

With the enthusiasm the science deserves and the patience the evidence requires.

The gap between a striking phase 1 and an approved treatment is usually five to ten years, and most things that look like this do not make it. We wrote about a rarer version of the same story, a therapy built for two children, in the personalised gene therapy case, and about the slower business of retraining an immune system with no engineering at all in oral immunotherapy for food allergy.

For anyone living with rheumatoid arthritis and reading this as news about their own treatment, the honest position is that nothing changes this year or next. What has changed is the direction of the field: the question is no longer whether autoimmune disease can be pushed into remission by borrowing from oncology, but whether it can be done affordably and safely enough to matter at scale.